Paul Chamberlain
Research Subjects
Paul Chamberlain has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Hans C. Ebbers
Biogen International GmbH Baar Switzerland
2 shared publications Pekka Kurki
Clinical Immunology, University of Helsinki
2 shared publicationsBonita Rup
Bonnie Rup Consulting, LLC, Reading, Massachusetts, USA
1 shared publication- Niamh M. Kinsella
Biogen Idec, Maidenhead, UK
1 shared publication - Peter C. Taylor
Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, UK
1 shared publication Tiina Reinivuori
Finnish Medicines Agency Fimea
1 shared publication
Latest Publications
- Open Access
- 8 April 2025
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 12 (3) , 529-546
A Comparison of the Immunogenicity of Intravenous BAT1806, a Tocilizumab Biosimilar, and Its Reference Product
Introduction Biosimilars need to demonstrate similarity in terms of quality, pharmacokinetics (PK), efficacy, safety, and immunogenicity. Here, we report the outcome of a comprehensive evaluation of the immunogenicity of the biosimilar BAT1806 compared with the tocilizumab reference product (TCZ). Methods We conducted a post hoc analysis of study BAT1806-001-CR, a comparative PK study in healthy male volunteers (n = 129), and BAT1806-002-CR, a phase III, 52-week trial in patients with rheumatoid arthritis (n = 621). Anti-drug antibodies (ADA), ADA titers, and neutralizing ADA were measured, and their impact on PK, safety, and efficacy parameters were assessed. Results In BAT1806-001-CR, treatment-induced ADA were observed in 37.8% of participants for the BAT1806 group, 28.6% for the EU-sourced TCZ group, and 31.0% for the US-sourced TCZ group, without an impact on PK and safety. In BAT1806-002-CR after 52 weeks, 28.2% of participants in the BAT1806 group developed treatment-induced ADA, compared with 24.0% in the TCZ group and 19.7% of participants who initiated TCZ and switched to BAT1806 at week 24. ADA-positive participants reported lower geometric mean serum tocilizumab trough concentrations than ADA-negative participants in all treatment groups. ADA-positive participants achieved similar efficacy outcomes to ADA-negative participants in all treatment groups. ADA were not associated with an incremental risk of treatment-emergent adverse events or hypersensitivity in any of the treatment groups. Conclusions The results of these post hoc analyses did not indicate any clinically relevant differences in the immunogenicity profile of intravenously administered BAT1806 compared with TCZ. Trial registration ClinicalTrials.gov identifiers, NCT03606876, NCT03830203.
- 8 April 2025
- Published by Springer Nature in Rheumatology and Therapy
- Vol. 12 (3) , 529-546
Open AccessA Comparison of the Immunogenicity of Intravenous BAT1806, a Tocilizumab Biosimilar, and Its Reference Product
Introduction Biosimilars need to demonstrate similarity in terms of quality, pharmacokinetics (PK), efficacy, safety, and immunogenicity. Here, we report the outcome of a comprehensive evaluation of the immunogenicity of the biosimilar BAT1806 compared with the tocilizumab reference product (TCZ). Methods We conducted a post hoc analysis of study BAT1806-001-CR, a comparative PK study in healthy male volunteers (n = 129), and BAT1806-002-CR, a phase III, 52-week trial in patients with rheumatoid arthritis (n = 621). Anti-drug antibodies (ADA), ADA titers, and neutralizing ADA were measured, and their impact on PK, safety, and efficacy parameters were assessed. Results In BAT1806-001-CR, treatment-induced ADA were observed in 37.8% of participants for the BAT1806 group, 28.6% for the EU-sourced TCZ group, and 31.0% for the US-sourced TCZ group, without an impact on PK and safety. In BAT1806-002-CR after 52 weeks, 28.2% of participants in the BAT1806 group developed treatment-induced ADA, compared with 24.0% in the TCZ group and 19.7% of participants who initiated TCZ and switched to BAT1806 at week 24. ADA-positive participants reported lower geometric mean serum tocilizumab trough concentrations than ADA-negative participants in all treatment groups. ADA-positive participants achieved similar efficacy outcomes to ADA-negative participants in all treatment groups. ADA were not associated with an incremental risk of treatment-emergent adverse events or hypersensitivity in any of the treatment groups. Conclusions The results of these post hoc analyses did not indicate any clinically relevant differences in the immunogenicity profile of intravenously administered BAT1806 compared with TCZ. Trial registration ClinicalTrials.gov identifiers, NCT03606876, NCT03830203.
- 14 April 2020
- Published by Springer Nature in The AAPS Journal
- Vol. 22 (3) , 1-13
Immunogenicity Risk Assessment for an Engineered Human Cytokine Analogue Expressed in Different Cell Substrates
The purpose of this article is to illustrate how performance of an immunogenicity risk assessment at the earliest stage of product development can be instr
- 14 April 2020
- Published by Springer Nature in The AAPS Journal
- Vol. 22 (3) , 1-13
Immunogenicity Risk Assessment for an Engineered Human Cytokine Analogue Expressed in Different Cell Substrates
The purpose of this article is to illustrate how performance of an immunogenicity risk assessment at the earliest stage of product development can be instr
- 14 December 2018
- Published by Springer Nature
- p. 489-542
Immunogenicity Assessment of Biosimilars: A Multidisciplinary Perspective
- 14 December 2018
- Published by Springer Nature
- p. 489-542
Immunogenicity Assessment of Biosimilars: A Multidisciplinary Perspective
- 6 April 2018
- Published by Springer Nature in Pharmaceutical Medicine
- Vol. 32 (2) , 103-121
Immunogenicity Assessment of Biosimilars
- 6 April 2018
- Published by Springer Nature in Pharmaceutical Medicine
- Vol. 32 (2) , 103-121
Immunogenicity Assessment of Biosimilars
- Open Access
- 13 January 2016
- Published by Springer Nature in BioDrugs
- Vol. 30 (1) , 1-8
Controversies in Establishing Biosimilarity: Extrapolation of Indications and Global Labeling Practices
The principles of establishing biosimilarity are to demonstrate structural and functional similarity to a reference product using the most discriminatory analytical methods. There is still considerable controversy on the scientific basis for extrapolation of indications for biosimilars, which has been strengthened by diverging global regulatory decision making. Closely related to the question of extrapolation is the question of how to communicate the evidence base for authorizing biosimilars to healthcare professionals. In this paper we will consider some of the discussions around extrapolation of indications and the implications of decisions of various regulatory agencies in the world regarding the authorization and labeling of biosimilars.
- 13 January 2016
- Published by Springer Nature in BioDrugs
- Vol. 30 (1) , 1-8
Open AccessControversies in Establishing Biosimilarity: Extrapolation of Indications and Global Labeling Practices
The principles of establishing biosimilarity are to demonstrate structural and functional similarity to a reference product using the most discriminatory analytical methods. There is still considerable controversy on the scientific basis for extrapolation of indications for biosimilars, which has been strengthened by diverging global regulatory decision making. Closely related to the question of extrapolation is the question of how to communicate the evidence base for authorizing biosimilars to healthcare professionals. In this paper we will consider some of the discussions around extrapolation of indications and the implications of decisions of various regulatory agencies in the world regarding the authorization and labeling of biosimilars.
- 20 February 2013
- Published by Taylor & Francis in Bioanalysis
- Vol. 5 (5) , 561-574
Assessing Immunogenicity of Biosimilar Therapeutic Monoclonal Antibodies: Regulatory and Bioanalytical Considerations
This article reflects on methodological limitations for interpretation of relative immunogenicity of biosimilar and reference therapeutic monoclonal antibodies, in emphasizing the relevance of correlation of bioanalytical signals with appropriate clinical end points, and the possible need for post-marketing observational studies to indicate the impact of detected differences in anti-drug antibody incidence and magnitude on sustainability of treatment benefit. Given the current uncertainty regarding the longer term clinical impact of undesirable immunogenicity for reference products, there can be no predefined margin for an acceptable difference based on incidence and magnitude of detected anti-drug antibodies. Any detected differences should be assessed in relation to clinical parameters; and the designation of biosimilarity made with reference to the similarity demonstrated in the directly comparative quality, nonclinical and clinical evaluations. Application of this 'totality of evidence' approach is illustrated for infliximab and adalimumab.
- 20 February 2013
- Published by Taylor & Francis in Bioanalysis
- Vol. 5 (5) , 561-574
Assessing Immunogenicity of Biosimilar Therapeutic Monoclonal Antibodies: Regulatory and Bioanalytical Considerations
This article reflects on methodological limitations for interpretation of relative immunogenicity of biosimilar and reference therapeutic monoclonal antibodies, in emphasizing the relevance of correlation of bioanalytical signals with appropriate clinical end points, and the possible need for post-marketing observational studies to indicate the impact of detected differences in anti-drug antibody incidence and magnitude on sustainability of treatment benefit. Given the current uncertainty regarding the longer term clinical impact of undesirable immunogenicity for reference products, there can be no predefined margin for an acceptable difference based on incidence and magnitude of detected anti-drug antibodies. Any detected differences should be assessed in relation to clinical parameters; and the designation of biosimilarity made with reference to the similarity demonstrated in the directly comparative quality, nonclinical and clinical evaluations. Application of this 'totality of evidence' approach is illustrated for infliximab and adalimumab.